摘要
在过去十年时间里,随着更加有效的新药被引进,成人心力衰竭的治疗得到了明显改善。治疗的重点已经从简单的血液动力学操作转向包括神经体液调节,尤其是在细胞水平的研究,以便更加了解心力衰竭形成机制。值得关注的是,儿童心力衰竭的病因与成人相比是非常不同并且多变的。儿童心力衰竭引发的原因主要为先天性心脏病和原发性心肌病;而对于成人,冠状动脉、高血压和心肌梗塞则是其心力衰竭形成的常见病因。尽管病因不同,但儿童心力衰竭病人的药物疗法却基于成人用药,通常参考成人心力衰竭病人的治疗方案。近期报道了一个关于儿童心力衰竭病人使用对成人非常有效的药物进行治疗的研究,值得欣慰的是治疗效果无明显差异。而有些报道则强调心力衰竭的儿童应该具有特定的用药指导,尤其是右心室或单心室衰竭病人。儿童心力衰竭病人药物疗法的通性就是缺少针对儿科的设计药物。目前用于治疗心力衰竭儿科用药是针对成人专门设计,其有效性、安全性和质量通常没有得到儿童临床研究确认。此外,一些标注为适用于儿童心力衰竭的商业药物制剂却到处可见,严重影响了治疗的质量和有效性。
关键词: 临床研究,剂型,心力衰竭,超出说明书功效药物,儿科,药物疗法
Current Medicinal Chemistry
Title:Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Volume: 21 Issue: 27
Author(s): M. Bajcetic, T. Vidonja Uzelac and I. Jovanovic
Affiliation:
关键词: 临床研究,剂型,心力衰竭,超出说明书功效药物,儿科,药物疗法
摘要: During the last decades, the introduction of new, more efficient drugs, has significantly improved the heart failure (HF) therapy of adults. Therapeutic focus has shifted from simple hemodynamic manipulation to include neurohumoral modulation as a consequence of the better understanding of mechanisms of HF formation, in particular at the cellular level. The aetiologies of HF in children are remarkably different and more varied than in the adult population. Cardiac failure is usually caused by congenital heart disease and cardiomyopathy in children, whereas in adults, coronary artery disease, hypertension and myocardial infarction are the most common causes. Despite this fact, pharmacotherapy of children is based on the same drugs, usually extrapolated from adult HF regimens. A recently published study in children treated with the drugs known to be efficient in adult HF therapy, provides encouragement that the outcomes might be similarly beneficial. On the other hand, some reports outline that children with HF, especially patients with systemic right ventricles or single ventricle physiology, require specific drug guidelines. A general characteristic of HF pharmacotherapy in children is the lack of paediatrically designed drugs. Drugs currently used in the treatment of HF in paediatric patients are designed for adults, and their efficacy, safety and quality have generally not been confirmed by clinical studies of children. Aside from this, availability of commercial paediatric drug formulations labelled for treatment of HF in children significantly influences the quality and efficacy of therapy.
Export Options
About this article
Cite this article as:
Bajcetic M., Vidonja Uzelac T. and Jovanovic I., Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients, Current Medicinal Chemistry 2014; 21 (27) . https://dx.doi.org/10.2174/0929867321666140303155453
DOI https://dx.doi.org/10.2174/0929867321666140303155453 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology New Analytical Tools for Studying Autoimmune Diseases
Current Pharmaceutical Design Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?
Cardiovascular & Hematological Agents in Medicinal Chemistry Takotsubo-Like Left Ventricular Dysfunction in an HIV-Infected Patient
Current HIV Research The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Use of Contrast Echocardiography in Intensive Care and at the Emergency Room
Current Cardiology Reviews Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry New Targeted Therapies for Thyroid Cancer
Current Genomics Matrix Metallopropteinases in Heart Failure
Current Topics in Medicinal Chemistry Wogonin Alleviates Hyperglycemia Through Increased Glucose Entry into Cells Via AKT/GLUT4 Pathway
Current Pharmaceutical Design A Comprehensive Literature Search: Drugs as Possible Triggers of Takotsubo Cardiomyopathy
Current Clinical Pharmacology TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook
Current Drug Targets Anti-T. cruzi Agents: Our Experience in the Evaluation of More than Five Hundred Compounds
Mini-Reviews in Medicinal Chemistry The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?
Current Medicinal Chemistry Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Current Pharmaceutical Design Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Genetic Privacy in Sports: Clearing the Hurdles
Recent Patents on DNA & Gene Sequences Patent Selections :
Recent Patents on Cardiovascular Drug Discovery